Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 24
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Am J Audiol ; 29(1): 18-22, 2020 Mar 05.
Artigo em Inglês | MEDLINE | ID: mdl-31940212

RESUMO

Purpose Long-term outcomes of sudden sensorineural hearing loss (SSNHL) are poorly studied. The recurrence rate is heterogeneous, and the prognosis of relapses is uncertain. The aim of this retrospective study was to evaluate the recurrence rate of SSNHL and to analyze the correlation with clinical and audiometric characteristics. Method Seventy-three patients with idiopatic SSNHL were evaluated. Clinical and audiometric features were recorded. Seventy patients (95.8%) had at least a 2-year follow-up, whereas 50 (68.4%) had a 5-year follow-up. Results Two- and 5-year recurrence rates were 5.60% and 10.34%, respectively. Mean time lapse between 1st episode and recurrence was 29.33 ± 26.60 months. About 70% of patients had a partial recovery at recurrence. The same ear was affected in 42.8% of patients, the contralateral ear was affected in 42.8% of patients, and recurrence was bilateral in 14.4% of cases. Recurrence correlated only with the presence of tinnitus during follow-up. However, the small number of participants with recurrence represented a limiting factor of our study. Conclusions Recurrences of SSNHL are rare events that can involve ipsilateral or contralateral ear. Further studies are necessary to identify predictors of recurrence.


Assuntos
Diuréticos Osmóticos/uso terapêutico , Glucocorticoides/uso terapêutico , Perda Auditiva Neurossensorial/terapia , Perda Auditiva Súbita/terapia , Oxigenoterapia Hiperbárica , Recuperação de Função Fisiológica , Administração Intravenosa , Administração Oral , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Audiometria de Tons Puros , Betametasona/uso terapêutico , Criança , Feminino , Perda Auditiva Neurossensorial/fisiopatologia , Perda Auditiva Súbita/fisiopatologia , Humanos , Injeção Intratimpânica , Estudos Longitudinais , Masculino , Manitol/uso terapêutico , Pessoa de Meia-Idade , Recidiva , Retratamento , Fatores de Tempo , Adulto Jovem
2.
J Am Anim Hosp Assoc ; 55(5): e55502, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31433221

RESUMO

ABSTRACT The use of bromethalin rodenticides has risen since 2011, and in some states, it is the most common rodenticide ingestion reported to poison control. Although intravenous lipid emulsion (ILE) has been previously reported to lower serum desmethylbromethalin levels in an asymptomatic dog, and repeated mannitol has been investigated in a laboratory setting, there are no published reports of successful treatment of symptomatic bromethalin toxicosis in dogs. A 9 yr old castrated male Norwich terrier was evaluated for obtunded mentation, seizures, cranial nerve deficits, and tetraparesis secondary to bromethalin toxicosis. The patient was treated with ILE, mannitol, and ginkgo biloba and returned to normal neurological function. Bromethalin exposure was confirmed by serum desmethylbromethalin levels. Previous literature indicates that the prognosis for patients who suffer from symptomatic bromethalin toxicosis is poor to grave, and the return to normal neurological function after severe toxicosis has not been reported. ILE, mannitol, and ginkgo biloba are readily available and relatively inexpensive, and in combination may be of benefit in symptomatic bromethalin intoxication.


Assuntos
Compostos de Anilina/intoxicação , Doenças do Cão/induzido quimicamente , Intoxicação/veterinária , Rodenticidas/intoxicação , Animais , Diuréticos Osmóticos/uso terapêutico , Doenças do Cão/terapia , Cães , Ginkgo biloba , Masculino , Manitol/uso terapêutico , Extratos Vegetais/uso terapêutico , Intoxicação/tratamento farmacológico , Intoxicação/patologia
3.
Br J Neurosurg ; 32(6): 619-627, 2018 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-30260251

RESUMO

Background: A prospective, randomized, double-blind study was designed to assess differences in brain relaxation between 2 doses of 3% HS during elective supratentorial brain tumour surgery.Methods: 60 patients undergoing supratentorial craniotomy for tumour resection were enrolled to receive either 3 mL/kg (group L) or 5 mL/kg (group H) of 3% HS administered at skin incision. Brain relaxation was assessed after dura opening on a scale ranging 1-4 (1 = perfectly relaxed, 2 = satisfactorily relaxed, 3 = firm brain, 4 = bulging brain). Hemodynamic variables and laboratory values (blood gases, osmolarity, haematocrit, and lactate) were collected before HS infusion and 30, 120 and 360 min after it. Presence of midline shift, postoperative complications, PCU and hospital stay, and mortality after 30 days were also recorded.Results: There was no difference in brain relaxation, with 2.0 (1.0-3.0) and 2.0 (1.0-2.3) (P = 0.535) for patients in groups L and H, respectively. If adjusted for the presence of midline shift, 50% of patients had adequate brain relaxation scores (grades 1 and 2) in group L and 61% in group H (OR 0.64, CI = 0.16-2.49, P = 0.515). No significant differences in perioperative outcome, mortality and length of PCU and hospital stay were observed.Conclusion: 3 mL/kg of 3% HS result in similar brain relaxation scores as 5 mL/kg in patients undergoing craniotomy for supratentorial brain tumour. This study reveals that both high and low doses of 3% HS may be less effective on intraoperative brain relaxation in patients with midline shift.


Assuntos
Craniotomia/métodos , Solução Salina Hipertônica/uso terapêutico , Neoplasias Supratentoriais/cirurgia , Encéfalo/efeitos dos fármacos , Encéfalo/cirurgia , Edema Encefálico/cirurgia , Diuréticos Osmóticos/uso terapêutico , Método Duplo-Cego , Procedimentos Cirúrgicos Eletivos , Feminino , Hemodinâmica/efeitos dos fármacos , Humanos , Masculino , Manitol/farmacologia , Pessoa de Meia-Idade , Complicações Pós-Operatórias/cirurgia , Estudos Prospectivos , Neoplasias Supratentoriais/fisiopatologia
4.
Hellenic J Cardiol ; 58(6): 427-431, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28065791

RESUMO

BACKGROUND: We investigated neuroprotective treatment strategies for patients with acute myocardial infarction (AMI) complicated with hypoxic ischemic encephalopathy (HIE) in the ICU. METHODS: The 83 cases diagnosed with secondary AMI were, for the first time, divided into an observation group (n = 43) and control group (n = 40). All of the patients underwent emergency or elective PCI. Patients in the control group were treated with mannitol to reduce intracranial pressure and cinepazide maleate to improve microcirculation in the brain as well as given a comprehensive treatment with oxygen inhalation, fluid infusion, acid-base imbalance correction and electrolyte disturbance. Patients in the observation group underwent conventional treatment combined with neuroprotective therapeutic strategies. The effects of the different treatment strategies were compared. RESULTS: Consciousness recovery time, reflex recovery time, muscle tension recovery time and duration of ICU stay were significantly shorter in the observation group compared with the control group (P < 0.05). After treatment, the jugular vein oxygen saturation (SjvO2) and blood lactate (JB-LA) levels of both groups were lower than before treatment and the cerebral oxygen utilization rate (O2UC) increased, with a significantly higher increase in the observation group (P < 0.05). After treatment, the activities of daily living (ADL) score was higher for both groups and the neural function defect (NIHS) score was lower. CONCLUSION: The neuroprotective strategies of hypothermia and ganglioside administration assisted with hyperbaric oxygen was effective for treating AMI patients with HIE and may be worth clinical promotion.


Assuntos
Encéfalo/efeitos dos fármacos , Hipóxia-Isquemia Encefálica/tratamento farmacológico , Infarto do Miocárdio/complicações , Infarto do Miocárdio/tratamento farmacológico , Atividades Cotidianas , Doença Aguda , Idoso , Encéfalo/irrigação sanguínea , Encéfalo/patologia , Diuréticos Osmóticos/uso terapêutico , Feminino , Gangliosídeos/uso terapêutico , Humanos , Oxigenoterapia Hiperbárica/métodos , Hipotermia , Hipóxia-Isquemia Encefálica/etiologia , Unidades de Terapia Intensiva , Tempo de Internação/estatística & dados numéricos , Masculino , Manitol/administração & dosagem , Manitol/uso terapêutico , Pessoa de Meia-Idade , Infarto do Miocárdio/diagnóstico , Infarto do Miocárdio/cirurgia , Fármacos Neuroprotetores/administração & dosagem , Fármacos Neuroprotetores/uso terapêutico , Observação/métodos , Oxigênio/administração & dosagem , Oxigênio/metabolismo , Oxigênio/uso terapêutico , Intervenção Coronária Percutânea/métodos , Piperazinas/administração & dosagem , Piperazinas/uso terapêutico , Vasodilatadores/uso terapêutico
5.
Crit Care ; 16(4): R159, 2012 Aug 17.
Artigo em Inglês | MEDLINE | ID: mdl-22901953

RESUMO

INTRODUCTION: Acute kidney injury (AKI), which is a major complication after cardiovascular surgery, is associated with significant morbidity and mortality. Diuretic agents are frequently used to improve urine output and to facilitate fluid management in these patients. Mannitol, an osmotic diuretic, is used in the perioperative setting in the belief that it exerts reno-protective properties. In a recent study on uncomplicated postcardiac-surgery patients with normal renal function, mannitol increased glomerular filtration rate (GFR), possibly by a deswelling effect on tubular cells. Furthermore, experimental studies have previously shown that renal ischemia causes an endothelial cell injury and dysfunction followed by endothelial cell edema. We studied the effects of mannitol on renal blood flow (RBF), glomerular filtration rate (GFR), renal oxygen consumption (RVO2), and extraction (RO2Ex) in early, ischemic AKI after cardiac surgery. METHODS: Eleven patients with AKI were studied during propofol sedation and mechanical ventilation 2 to 6 days after complicated cardiac surgery. All patients had severe heart failure treated with one (100%) or two (73%) inotropic agents and intraaortic balloon pump (36%). Systemic hemodynamics were measured with a pulmonary artery catheter. RBF and renal filtration fraction (FF) were measured by the renal vein thermo-dilution technique and by renal extraction of chromium-51-ethylenediaminetetraacetic acid (51Cr-EDTA), respectively. GFR was calculated as the product of FF and renal plasma flow RBF × (1-hematocrit). RVO2 and RO2Ex were calculated from arterial and renal vein blood samples according to standard formulae. After control measurements, a bolus dose of mannitol, 225 mg/kg, was given, followed by an infusion at a rate of 75 mg/kg/h for two 30-minute periods. RESULTS: Mannitol did not affect cardiac index or cardiac filling pressures. Mannitol increased urine flow by 61% (P < 0.001). This was accompanied by a 12% increase in RBF (P < 0.05) and a 13% decrease in renal vascular resistance (P < 0.05). Mannitol increased the RBF/cardiac output (CO) relation (P = 0.040). Mannitol caused no significant changes in RO2Ext or renal FF. CONCLUSIONS: Mannitol treatment of postoperative AKI induces a renal vasodilation and redistributes systemic blood flow to the kidneys. Mannitol does not affect filtration fraction or renal oxygenation, suggestive of balanced increases in perfusion/filtration and oxygen demand/supply.


Assuntos
Injúria Renal Aguda/tratamento farmacológico , Injúria Renal Aguda/fisiopatologia , Procedimentos Cirúrgicos Cardíacos/efeitos adversos , Diuréticos Osmóticos/uso terapêutico , Rim/efeitos dos fármacos , Manitol/uso terapêutico , Injúria Renal Aguda/etiologia , Idoso , Feminino , Taxa de Filtração Glomerular/efeitos dos fármacos , Hemodinâmica/efeitos dos fármacos , Humanos , Rim/irrigação sanguínea , Rim/metabolismo , Masculino , Consumo de Oxigênio/efeitos dos fármacos , Estudos Prospectivos , Circulação Renal/efeitos dos fármacos , Resistência Vascular/efeitos dos fármacos , Vasodilatação/efeitos dos fármacos
6.
Rev Bras Anestesiol ; 61(4): 456-68, 2011.
Artigo em Inglês, Mul | MEDLINE | ID: mdl-21724008

RESUMO

BACKGROUND AND OBJECTIVES: Cerebral relaxation during intracranial surgery is necessary, and hiperosmolar therapy is one of the measures used to this end. Frequently, neurosurgical patients have sodium imbalances. The objective of the present study was to quantify and determine cerebral relaxation and duration of hydroelectrolytic changes secondary to the use of mannitol versus hypertonic isoncotic solution (HIS) during neurosurgery. METHODS: Cerebral relaxation and hydroelectrolytic changes were evaluated in 29 adult patients before de beginning of infusion, and 30 and 120 minutes after the infusion of equiosmolar loads of approximately 20% mannitol (250 mL) or HIS (120 mL). The volume of intravenous fluids infused and diuresis were recorded. A p < 0.05 was considered significant. RESULTS: A statistically significant difference in cerebral relaxation between both groups was not observed. Although several changes in electrolyte levels and acid-base balance with mannitol or HIS reached statistical significance only the reduction in plasma sodium 30 minutes after infusion of mannitol, mean of 6.42 ± 0.40 mEq.L(-1), and the increase in chloride, mean of 5.41 ± 0.96 mEq.L(-1) and 5.45 ± 1.45 mEq.L(-1) 30 and 120 minutes after infusion of HIS, caused a transitory dislocation of serum ion levels from normal range. The mannitol (20%) group had a significantly greater diuresis at both times studied compared with HIS group. CONCLUSIONS: A single dose of hypertonic isoncotic saline solution [7.2% NaCl/6% HES (200/0.5)] and mannitol (20%) with equivalent osmolar loads were effective and safe in producing cerebral relaxation during elective neurosurgical procedures under general anesthesia.


Assuntos
Anestesia , Encéfalo/cirurgia , Craniotomia , Diuréticos Osmóticos/uso terapêutico , Soluções Hipertônicas/uso terapêutico , Manitol/uso terapêutico , Equilíbrio Hidroeletrolítico , Adulto , Feminino , Humanos , Masculino
7.
Adv Pediatr ; 55: 99-121, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-19048729

RESUMO

In summary, there is a significant interplay between the pulmonary manifestations and nutritional status of CF patients. The advances in CF clinical care in the past 2 decades are mainly attributed to anti-infective therapy as well as aggressive nutritional management. Currently, there are multiple therapeutic agents that are in clinical trial that target either the underlying CFTR defect or the downstream effects of CFTR. The broad spectrum of therapeutic agents being studied as well as the advances in therapies that target the underlying CFTR defect are exciting, making it likely that at least one of the treatments will make a major difference in how we will treat CF in the future.


Assuntos
Fibrose Cística/fisiopatologia , Fibrose Cística/terapia , Anti-Infecciosos/uso terapêutico , Anti-Inflamatórios/uso terapêutico , Fibrose Cística/genética , Regulador de Condutância Transmembrana em Fibrose Cística/genética , Diabetes Mellitus/fisiopatologia , Diuréticos Osmóticos/uso terapêutico , Expectorantes/uso terapêutico , Terapia Genética , Humanos , Inflamação/metabolismo , Pulmão/fisiopatologia , Desnutrição/fisiopatologia , Desnutrição/prevenção & controle , Manitol/uso terapêutico , Neutrófilos/metabolismo , Infecções Respiratórias/etiologia
8.
Eksp Klin Farmakol ; 70(3): 50-2, 2007.
Artigo em Russo | MEDLINE | ID: mdl-17650635

RESUMO

Effect of the intravenous injection of polyosm (30% solution of polyethylene oxide with a molecular mass of 400, PEO-400) was investigated on Wistar rats with a model of brain edema induced by a freezing lesion in one cerebral hemisphere. The brain edema development was estimated by measuring the active resistance of tissues in the right and left parietal cortex and the content of water in both hemispheres. A course of the intravenous injections of polyosm (1 g/kg of PEO-400 daily during 3 days) after the model lesion onset decreased the initially elevated active resistance in the edematous cerebral tissue and reduced water accumulation in the damaged hemisphere.


Assuntos
Edema Encefálico/tratamento farmacológico , Lesões Encefálicas/complicações , Diuréticos Osmóticos/uso terapêutico , Polietilenoglicóis/uso terapêutico , Animais , Química Encefálica , Edema Encefálico/etiologia , Diuréticos Osmóticos/administração & dosagem , Congelamento , Masculino , Polietilenoglicóis/administração & dosagem , Ratos , Ratos Wistar , Água/análise
9.
ANZ J Surg ; 76(3): 163-74, 2006 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-16626360

RESUMO

BACKGROUND: Traumatic brain injury is a major cause of mortality and morbidity, particularly among young men. The efficacy and safety of most of the interventions used in the management of patients with traumatic brain injury remain unproven. Examples include the 'cerebral perfusion pressure-targeted' and 'volume-targeted' management strategies for optimizing cerebrovascular haemodynamics and specific interventions, such as hyperventilation, osmotherapy, cerebrospinal fluid drainage, barbiturates, decompressive craniectomy, therapeutic hypothermia, normobaric hyperoxia and hyperbaric oxygen therapy. METHODS: A review of the literature was performed to examine the evidence base behind each intervention. RESULTS: There is no class I evidence to support the routine use of any of the therapies examined. CONCLUSION: Well-designed, large, randomized controlled trials are needed to determine therapies that are safe and effective from those that are ineffective or harmful.


Assuntos
Lesões Encefálicas/terapia , Manitol/uso terapêutico , Barbitúricos/farmacologia , Barbitúricos/uso terapêutico , Lesões Encefálicas/fisiopatologia , Lesões Encefálicas/cirurgia , Descompressão Cirúrgica , Diuréticos Osmóticos/uso terapêutico , Drenagem , Hemodinâmica , Humanos , Oxigenoterapia Hiperbárica , Hipotermia , Pressão Intracraniana/efeitos dos fármacos , Solução Salina Hipertônica/uso terapêutico , Crânio/cirurgia
10.
J Emerg Med ; 24(3): 285-8, 2003 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12676299

RESUMO

Western diamondback rattlesnake envenomation is usually managed by administration of neutralizing antivenom. The development of compartment syndrome is a rare complication that has sparked considerable debate regarding medical vs. surgical management. We report a case of compartment syndrome resulting from a rattlesnake envenomation, which responded to large doses of neutralizing antivenom given concomitantly with mannitol and hyperbaric oxygen. This regimen obviated the need for surgical fasciotomy and its associated morbidity.


Assuntos
Síndromes Compartimentais/etiologia , Síndromes Compartimentais/terapia , Crotalus , Oxigenoterapia Hiperbárica , Mordeduras de Serpentes/complicações , Adulto , Animais , Antivenenos/uso terapêutico , Venenos de Crotalídeos , Diuréticos Osmóticos/uso terapêutico , Humanos , Masculino , Manitol/uso terapêutico
11.
J Cataract Refract Surg ; 29(3): 588-91, 2003 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-12663028

RESUMO

Shallowing of the anterior chamber and hardening of the eye occurred just before commencement of irrigation/aspiration of cortex in an 80-year-old man having temporal clear corneal cataract surgery under topical and intracameral anesthesia. Nucleus removal had been completed and was uneventful. Intraoperative fundus examination with the indirect ophthalmoscope disclosed a choroidal hemorrhage. The wound was immediately closed with sutures, and intravenous mannitol was administered. The hemorrhage remained localized. The red reflex remained unchanged at all times, and there was no prolapse of intraocular contents. A high index of suspicion is critical to the early diagnosis and management of choroidal hemorrhage.


Assuntos
Anestesia Local/métodos , Hemorragia da Coroide/etiologia , Complicações Intraoperatórias , Facoemulsificação/efeitos adversos , Doença Aguda , Idoso , Idoso de 80 Anos ou mais , Hemorragia da Coroide/terapia , Terapia Combinada , Córnea/cirurgia , Diuréticos Osmóticos/uso terapêutico , Humanos , Masculino , Manitol/uso terapêutico
12.
Herz ; 27(2): 135-49, 2002 Mar.
Artigo em Alemão | MEDLINE | ID: mdl-12025459

RESUMO

PATHOGENESIS: All forms of chronic heart failure (high-output and low-output failure) are accompanied by an "arterial underfilling" inducing the activation of various neurohumoral systems (renin-angiotensin-aldosterone system, sympathic nervous system, non-osmotic stimulation of vasopressin). Elevated levels of those neurohormones detrimentally modulate renal function. Subsequently, renal salt and volume retention occurs leading to the main symptoms of heart failure, edema formation and dyspnea. DIURETIC THERAPY: Diuretics, which have been discovered more than 40 years ago, beneficially influence renal salt- and volume retention by their effects on tubular sodium reabsorption. While thiazides are recommended in mild forms, loop diuretics are used in severe stages of congestive heart failure. The clinician has to consider the changed pharmacokinetic and -dynamic properties during the application of diuretics in patients with chronic heart failure. In addition, increased sodium reabsorption occurs immediately after cessation of diuretic action often nullifying the preceding diuresis. Thus, salt- and volume restriction should be guaranteed, and a regular application of loop diuretics during the day should be preferred due to the short-acting nature of currently available loop diuretics. Sometimes, diuresis does not longer occur during the treatment with one substance (diuretic resistance), although the therapeutic goals of water excretion have not been achieved. After ruling out factors reducing the actions of diuretics (non-compliance, hyponatremia, etc.), a sequential nephron blockade should be initiated (combination of loop diuretics and a thiazide or an aldosterone-receptor antagonist) to increase diuresis and to elevate symptoms of volume overload. SIDE EFFECTS: Loop diuretics and thiazides often induce mild hypokalemia, which has been demonstrated to be not as benign as thought before. Chronic treatment with oral potassium supplements has several drawbacks, as urine excretion of potassium is subsequently increased and supplementation is not as effective as believed. Diuretic-induced hypokalemia seems to be aldosterone dependent. As aldosterone levels increase during diuretic therapy even during chronic treatment with an angiotensin-converting enzyme (aldosterone-escape) a combined treatment including an aldosterone-receptor antagonist has been suggested. Beneficial effects of aldosterone-receptor blockade on mortality (RALES trial) appear to be mediated be extrarenal and renal mechanisms. The suggested beneficial renal mechanisms of aldosterone receptor blockade are discussed in detail in the review. CONCLUSION: In conclusion, diuretic therapy of patients with congestive heart failure is effective to relieve symptoms and, presumably, to prolong life. As renal function and pharmacokinetics and -dynamics of diuretics are changed in heart failure, diuretic treatment has to be adapted to provide optimal treatment. Increased levels of aldosterone appear to play an important role in diuretic-induced hypokalemia, and in the progression of heart and renal failure. Thus, aldosterone receptor antagonists should be used in the treatment of heart failure more frequently.


Assuntos
Diuréticos/uso terapêutico , Insuficiência Cardíaca/tratamento farmacológico , Antagonistas de Receptores de Mineralocorticoides , Benzotiadiazinas , Diuréticos/efeitos adversos , Diuréticos Osmóticos/efeitos adversos , Diuréticos Osmóticos/uso terapêutico , Quimioterapia Combinada , Insuficiência Cardíaca/fisiopatologia , Hemodinâmica/efeitos dos fármacos , Hemodinâmica/fisiologia , Humanos , Receptores de Mineralocorticoides/fisiologia , Inibidores de Simportadores de Cloreto de Sódio/efeitos adversos , Inibidores de Simportadores de Cloreto de Sódio/uso terapêutico , Equilíbrio Hidroeletrolítico/efeitos dos fármacos , Equilíbrio Hidroeletrolítico/fisiologia
13.
Crit Care Med ; 30(3): 644-9, 2002 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-11990928

RESUMO

OBJECTIVE: Isolated experiments suggest that global cerebral edema is a sequela of large hemispheric ischemic lesions, presumably as an extension of the initial ischemic insult into areas of vital, noninjured tissue. Diuretics and osmotic agents are controversial and poorly defined therapeutic modalities after large infarction. By using a rat model of middle cerebral artery occlusion (MCAO), we tested the hypothesis that significant edema occurs in the contralateral uninjured hemisphere and that this postischemic complication can be manipulated by hypertonic saline therapy. DESIGN: Prospective laboratory animal study. SETTING: Research laboratory in a teaching hospital. SUBJECTS: Halothane-anesthetized, male Wistar rats. INTERVENTIONS: Under controlled conditions of normoxia, normocarbia, and normothermia, rats were subjected to 2 hrs of MCAO. MEASUREMENTS AND MAIN RESULTS: Adequacy of MCAO and reperfusion was assessed by laser Doppler flowmetry. All animals except naive rats received continuous infusion of 0.9% saline at 0.5 mL/hr throughout the experiment. Brains were harvested, and tissue water content was estimated by comparing the wet-to-dry weight ratios of ipsilateral and contralateral cerebral hemispheres at 12 hrs, 24 hrs, or 2, 3, or 7 days postischemia. Naive and sham-operated rats served as control cohorts. In a second series of randomized experiments, wet-to-dry weight ratios were determined in rats treated with continuous intravenous infusion of 7.5% hypertonic saline (0.5 mL/hr; acetate/chloride, 50:50) and were compared with well-studied antiedema therapy: 20% mannitol (2.5 g/kg bolus every 6 hrs) or furosemide (2.5 mg/kg bolus every 6 hrs). Treatments were started at 24 hrs of reperfusion, and brain water was assessed at 2 days of reperfusion. In a third series of experiments, wet-to-dry ratios were determined in brains harvested at 2 days of reperfusion from rats that were subjected to 2 hrs of MCAO and did not receive any intravenous fluids. All values are mean +/- SEM. There were no differences between sham-operated and naive control cohorts. At 24 hrs of reperfusion, water content was higher in both ipsilateral ischemic (82.80 +/- 0.86%) and contralateral hemispheres (80.53 +/- 0.29%), compared with naive animals (ipsilateral, 79.62 +/- 0.12%; contralateral, 79.53 +/- 0.13%). Maximal cerebral edema was measured at 2 days in both hemispheres (ipsilateral, 83.94 +/- 0.47%; contralateral, 80.63 +/- 0.13%). Edema was present for up to 3 days in contralateral tissue (80.27 +/- 0.26%) and persisted to 7 days in the injured hemisphere (81.07 +/- 0.34%). Maximal edema (as assessed at 2 days postocclusion) was robustly attenuated with hypertonic saline therapy (ipsilateral, 81.59 +/- 0.52%; contralateral, 78.44 +/- 0.22%). The efficacy of hypertonic saline was equivalent to furosemide (ipsilateral, 82.09 +/- 0.50%; contralateral, 79.13 +/- 0.17%) but less robust than mannitol (ipsilateral, 79.89 +/- 0.36%; contralateral, 78.73 +/- 0.17%). CONCLUSIONS: These data demonstrate that cerebral edema persists in both injured and contralateral hemispheres for days after MCAO. The global, maximal increase in brain water is responsive to continuous 7.5% hypertonic saline treatment begun at 24 hrs postischemia and to standard diuretic/osmotic agents. These results may have implications for diuretic and osmotic therapy in clinical ischemic stroke.


Assuntos
Edema Encefálico/tratamento farmacológico , Edema Encefálico/etiologia , Isquemia Encefálica/complicações , Infarto da Artéria Cerebral Média/complicações , Solução Salina Hipertônica/uso terapêutico , Análise de Variância , Animais , Diuréticos/farmacologia , Diuréticos/uso terapêutico , Diuréticos Osmóticos/farmacologia , Diuréticos Osmóticos/uso terapêutico , Furosemida/farmacologia , Furosemida/uso terapêutico , Masculino , Manitol/farmacologia , Manitol/uso terapêutico , Ratos , Ratos Wistar , Solução Salina Hipertônica/farmacologia
14.
J Tradit Chin Med ; 20(1): 3-9, 2000 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-10921160

RESUMO

The therapeutic effect of Zhu Yu Hua Tan Tang ([symbol: see text] Decoction for removing blood stasis and resolving phlegm) plus general and modern treatment on acute cerebral hemorrhage in 44 cases, and the pressure-lowering effect of Zhu Yu Hua Tan Tang and mannitol in 20 cases of acute cerebral hemorrhage in the basilar region, and in rabbits with experimental encephaledema induced by injection of olive oil into the common carotid artery were observed in this study. The results showed that Zhu Yu Hua Tan Tang plus general treatment can better improved the conscious state of the patients than western medicine, and it can make the intracranial pressure drop clinically by 40.44%. The intracranial pressure-lowering effect of Zhu Yu Hua Tan Tang, though slow, is smooth and long-lasting without any rebound phenomenon, as compared to those of mannitol. Similar results were found in animal experiments, but the intracranial pressure-lowering amplitude of Zhu Yu Hua Tan Tang was stronger than that of mannitol. The difference between the clinical and experimental results needs to be further studied.


Assuntos
Hemorragia Cerebral/tratamento farmacológico , Medicamentos de Ervas Chinesas/uso terapêutico , Pressão Intracraniana/efeitos dos fármacos , Idoso , Animais , Hemorragia Cerebral/fisiopatologia , Diuréticos Osmóticos/uso terapêutico , Feminino , Humanos , Masculino , Manitol/uso terapêutico , Pessoa de Meia-Idade , Coelhos
15.
Neurosci Lett ; 272(3): 143-5, 1999 Sep 17.
Artigo em Inglês | MEDLINE | ID: mdl-10505601

RESUMO

A cryogenic lesion was produced under halothane anaesthesia in the mouse by placing a cotton swab soaked in liquid nitrogen onto the surface of the cranium. This provoked an oedematous lesion which developed within the hour after the insult and evolved over the following week. Treatment with mannitol at 3 g/kg i.v. caused a significant 22% reduction in oedema 1 h later, when administered immediately after lesion, but not when administered 23-h post lesion. Likewise riluzole (16 mg/kg, i.v.) significantly reduced oedema by 17% when administered immediately after lesion, or 13% (P < 0.05) when administered 23 h after lesion. Repeated doses (2 x 16 mg/kg, i.p.) of riluzole were also able to reduce oedema significantly (24%, P < 0.05) at 24 h post lesion. Riluzole, in four repeated doses of 8 mg/kg i.p. was also able to reduce lesion surface size by 16% (P < 0.05) 48 h after lesion.


Assuntos
Edema Encefálico/tratamento farmacológico , Lesão Encefálica Crônica/tratamento farmacológico , Diuréticos Osmóticos/uso terapêutico , Congelamento , Manitol/uso terapêutico , Fármacos Neuroprotetores/uso terapêutico , Riluzol/uso terapêutico , Animais , Química Encefálica/efeitos dos fármacos , Edema Encefálico/patologia , Lesão Encefálica Crônica/patologia , Masculino , Camundongos , Água/metabolismo
16.
Eksp Klin Farmakol ; 60(2): 72-4, 1997.
Artigo em Russo | MEDLINE | ID: mdl-9206578

RESUMO

Experiments were conducted on Wistar rats to study the effect of intravenous infusion of polyosm (solution of polyethyleneoxide 400) on the parameters of brain tissue edema-swelling (according to impedancemetry findings) and the local cerebral blood flow on a model of acute hypertensive encephalopathy. Under such conditions the drug hastened involution of edema-swelling of the brain tissue and prevented a decrease in cerebral blood flow.


Assuntos
Edema Encefálico/tratamento farmacológico , Diuréticos Osmóticos/uso terapêutico , Hipertensão/tratamento farmacológico , Polietilenoglicóis/uso terapêutico , Doença Aguda , Animais , Edema Encefálico/induzido quimicamente , Modelos Animais de Doenças , Avaliação Pré-Clínica de Medicamentos , Hipertensão/induzido quimicamente , Masculino , Norepinefrina , Papaverina/análogos & derivados , Ratos , Ratos Wistar , Estatísticas não Paramétricas
17.
Intensive Care Med ; 22(5): 434-8, 1996 May.
Artigo em Inglês | MEDLINE | ID: mdl-8796395

RESUMO

OBJECTIVE: To determine whether intravenous mannitol administration reduces intracranial pressure (ICP) in a cat model of brain edema by changing serum osmolality. DESIGN: Prospective, controlled study. SETTING: Pediatric intensive care unit laboratory in a university hospital. INTERVENTIONS: Intraparenchymal ICP monitors were placed in 12 adult cats which subsequently underwent 60 min of continuous arteriovenous hemofiltration with countercurrent dialysis (CAVH-D), using sterile water with potassium chloride as a dialysate. The ultrafiltrate was replaced with a hypotonic solution causing a rapid reduction in serum osmolality while maintaining a euvolemic state. In six cats (control group) no further interventions were instituted, while in the six other cats (mannitol group) 1g/kg mannitol was administered intravenously immediately after CAVH-D had been discontinued. ICP was monitored continuously, and serum osmolality was determined at 15-min intervals during CAVH-D and for 30 min thereafter. RESULTS: ICP increased significantly in both the control and mannitol groups during 60 min of CAVH-D. After CAVH-D, ICP was reduced in the mannitol group while ICP remained significantly higher in the control group. An inverse linear correlation was demonstrated between serum osmolality and ICP values in the control group throughout the experiment, as well as during the first 60 min in the mannitol group. However, no such correlation existed in the mannitol group after mannitol administration, as no significant changes in serum osmolality were observed while a marked reduction in ICP values occurred. CONCLUSION: Mannitol is effective in reducing increased ICP in this model of euvolemic brain edema. However, 15 min after mannitol administration, no relationship between a continued decrease in ICP and a change in serum osmolality could be established. We postulate that the beneficial effect on ICP by mannitol outlasts its possible instantaneous and short-lived effect on serum osmolality.


Assuntos
Edema Encefálico/tratamento farmacológico , Diuréticos Osmóticos/uso terapêutico , Pressão Intracraniana/efeitos dos fármacos , Manitol/uso terapêutico , Animais , Edema Encefálico/sangue , Edema Encefálico/fisiopatologia , Gatos , Modelos Animais de Doenças , Avaliação Pré-Clínica de Medicamentos , Monitoramento de Medicamentos , Hemodiafiltração , Infusões Intravenosas , Modelos Lineares , Concentração Osmolar , Fatores de Tempo
18.
Am J Emerg Med ; 14(1): 27-32, 1996 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-8630150

RESUMO

The purpose of this study was to evaluate the effects of mannitol (Man), dexamethasone (DM), dichloroacetic acid (DCA) and 1,3-butanediol (BD) in reduction of posttraumatic cortical edema following brain deformation injury to rats. Ten minutes prior to fluid percussion injury, each animal received one of four pretreatments or placebo: Man, 1 g/kg intravenously, DM 3.0 mg/kg intravenously, DCA 25 mg/kg intraperitoneally BD 0.5 mg/kg intraperitoneally (n = 12 per treatment group), or equivolume saline (n = 8 per corresponding trauma group). Six hours after trauma, cortical tissue was harvested. Using a benzene-kerosene gradient column calibrated with potassium sulfate standards, the specific gravity (SpG) of cortical tissue from each group was measured and compared (ANOVA, P < .05). The measured cortical SpG from traumatized animals receiving Man (mean 1.037 +/- SEM .001), DCA (1.038 +/- .001), and BD (1.039 +/- .001) were equal to SpG from untraumitized cortex (1.041 +/- .001), and were significantly greater than SpG from traumatized cortex for animals receiving DM (1.035 +/- .001) or placebo (1.033 +/- .002). Pretreatment with DCA, Man, and BD appears to protect against development of posttraumatic cortical edema when measured 6 hours after blunt head trauma in the rat. Each of these chemical treatments appears effective in preventing or reducing posttraumatic cortical edema.


Assuntos
Anti-Inflamatórios/uso terapêutico , Edema Encefálico/tratamento farmacológico , Lesões Encefálicas/complicações , Butileno Glicóis/uso terapêutico , Dexametasona/uso terapêutico , Ácido Dicloroacético/uso terapêutico , Diuréticos Osmóticos/uso terapêutico , Manitol/uso terapêutico , Pré-Medicação/métodos , Animais , Edema Encefálico/etiologia , Avaliação Pré-Clínica de Medicamentos , Humanos , Masculino , Ratos , Ratos Sprague-Dawley , Gravidade Específica , Fatores de Tempo
19.
Med Clin (Barc) ; 105(18): 681-6, 1995 Nov 25.
Artigo em Espanhol | MEDLINE | ID: mdl-8538248

RESUMO

BACKGROUND: Pneumococcal meningitis (PM) is an infection with high morbidity and mortality. The aim of this study was to evaluate the most relevant clinical, epidemiologic and evolutive characteristics of a recent series of adult patients with this disease. METHODS: Over a period of 10 years all the patients with PM diagnosed by isolation of this microorganism in the cerebrospinal fluid (CSF) were evaluated from a clinical, therapeutic and evolutive points of view. The impact of the new therapies in the disease and the variables associated with mortality were analyzed. RESULTS: Seventy episodes of PM were diagnosed, 60% being found in patients over the age of 50 years. The male/female relationship was 2/1. Fifty-three percent of the patients had other underlying diseases. Acute otitis media (AOM) was the source in 34% of the cases, in 11% the patients had a fistula of CSF and in 9% a pneumonia. At the time of diagnosis 74% of the patients had some degree of reduction in the level of consciousness and in 40% of the episodes the presence of neurologic local manifestations were observed. A decrease in sensitivity to penicillin was observed in 33% of the microorganisms isolated. Third generation cephalosporins were used as initial treatment in 57 episodes and penicillin in other 11 episodes. Adjuvant treatment with dexamethasone, mannitol and/or diphenylhydantoin was administered in 54% of the patients. Overall mortality was 23%: the factors associated with an unfavourable evolution were the existence of underlying disease, deep alteration in the level of consciousness at the time of diagnosis, the coexistence of pneumonia and the absence of adjuvant therapy. CONCLUSIONS: Mortality in pneumococcal meningitis is high. The most relevant risk factor is the initial degree of consciousness. Adjuvant therapies probably determine a reduction in the rate of mortality.


Assuntos
Meningite Pneumocócica , Adulto , Fatores Etários , Idoso , Anticonvulsivantes/uso terapêutico , Cefalosporinas/uso terapêutico , Dexametasona/uso terapêutico , Diuréticos Osmóticos/uso terapêutico , Feminino , Glucocorticoides/uso terapêutico , Humanos , Masculino , Manitol/uso terapêutico , Meningite Pneumocócica/tratamento farmacológico , Meningite Pneumocócica/mortalidade , Pessoa de Meia-Idade , Penicilina G/uso terapêutico , Penicilinas/uso terapêutico , Fenitoína/uso terapêutico , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA